Authorized Generics Deal Cleared Of Antitrust Charges

Law360, New York (November 7, 2005, 12:00 AM EST) -- An appeals court has upheld a lower court decision that cleared two major drug makers of antitrust charges in a decision that once again spotlights the debate over authorized generics.

The U.S. Court of Appeals for the Second Circuit sided with a district court judge’s decision to dismiss a class action suit against Barr Laboratories and AstraZeneca Pharmaceuticals that accused the two companies of artificially inflating the price of cancer fighter Tamoxifen Citrate.

“We are pleased that our patent challenge settlement related to Tamoxifen has been...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.